Basic Mechanisms of Antibiotic Action and Resistance

Basic Mechanisms of Antibiotic Action and

Resistance

https://science.umd.edu/classroom/bsci424/Images/EarthBlueBall.gif

Five Basic Mechanisms of Antibiotic 

Action against Bacterial Cells:

1. Inhibition of Cell Wall Synthesis (most common mechanism)

2. Inhibition of Protein Synthesis (Translation) (second largest class)

3. Alteration of Cell Membranes

4. Inhibition of Nucleic Acid Synthesis

5. Antimetabolite Activity

 

Inhibition of Cell Wall Synthesis

Beta-Lactams ---> Inhibition of peptidoglycan synthesis (bactericidal)

Resistance --->

(1)     fails to cross membrane (gram negatives)

(2)     fails to bind to altered PBPs

(3)     hydrolysis by beta-lactamases

Vancomycin ---> Disrupts peptidoglycan cross- linkage

Resistance --->

(1)     fails to cross gram negative outer membrane (too large)

(2)     some intrinsically resistant (pentapeptide terminus)

Bacitracin ---> Disrupts movement of peptidoglycan precursors (topical use)

Resistance ---> fails to penetrate into cell

Antimycobacterial agents ---> Disrupt mycolic acid or arabinoglycan synthesis (bactericidal) 

Resistance --->

(1)     reduced uptake

(2)     alteration of target sites

Inhibition of Protein Synthesis (Translation)

 



30S Ribosome site

Aminoglycosides ---> Irreversibly bind 30S ribosomal proteins (bactericidal)

Resistance --->

(1)     mutation of ribosomal binding site

(2)     decreased uptake

(3)     enzymatic modification of antibiotic

Tetracyclines ---> Block tRNA binding to 30S ribosome-mRNA complex (b-static)

Resistance --->

(1)     decreased penetrate 

(2)     active efflux of antibiotic out of cell

(3)     protection of 30S ribosome



50S Ribosome site

Chloramphenicol ---> Binds peptidyl transferase component of 50S ribosome, blocking peptide elongation (bacteriostatic)

Resistance --->

(1) plasmid-encoded chloramphenicol transferase
(2)      altered outer membrane (chromosomal mutations)

Macrolides ---> Reversibly bind 50S ribosome, block peptide elongation (b- static)

Resistance --->

(1)     methylation of 23S ribosomal RNA subunit

(2)     enzymatic cleavage (erythromycin esterase)

(3)     active efflux

Clindamycin ---> Binds 50S ribosome, blocks peptide elongation; Inhibits peptidyl transferase by interfering with binding

of amino acid-acyl-tRNA complex

Resistance ---> methylation of 23S ribosomal RNA subunit



 

Inhibition of Nucleic Acid Synthesis

 DNA Effects

Quinolones ---> Inhibit DNA gyrases or topoisomerases required for supercoiling of DNA; bind to the alpha subunit

Resistance --->

(1)     alteration of alpha subunit of DNA gyrase (chromosomal)

(2)     decreased uptake by alteration of porins (chromosomal)

Metronidazole ---> Metabolic cytotoxic by-products disrupt DNA

Resistance --->

(1)     decreased uptake

(2)     elimination of toxic compounds before they interact

 

 RNA Effects (Transcription)

Rifampin ---> Binds to DNA-dependent RNA polymerase inhibiting initiation & Rifabutin of RNA synthesis

Resistance --->

(1)     altered of beta subunit of RNA polymerase (chromosomal)

(2)     intrinsic resistance in gram negatives (decreased uptake)

Bacitracin (topical) ---> Inhibits RNA transcription

Resistance ---> inability to penetrate outer membrane

 

Antimetabolite Activity

Sulfonamides & Dapsone ---> Compete with p-aminobenzoic acid (PABA) preventing synthesis of folic acid

Resistance ---> permeability barriers (e.g., Pseudomonas)

Trimethoprim ---> Inhibit dihydrofolate reductase preventing synthesis of folic acid

Resistance --->

(1)     decreased affinity of dihydrofolate reductase

(2)     intrinsic resistance if use exogenous thymidine Trimethoprim-Sulfamethoxazole

 


Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more